Free Trial
NYSE:NUVB

Nuvation Bio Q2 2024 Earnings Report

Nuvation Bio logo
$2.20 +0.01 (+0.23%)
As of 02:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nuvation Bio EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.06
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Nuvation Bio Revenue Results

Actual Revenue
$1.44 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nuvation Bio Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Monday, August 5, 2024
Conference Call Time
8:30AM ET

Upcoming Earnings

Nuvation Bio's Q2 2025 earnings is scheduled for Monday, August 4, 2025, with a conference call scheduled on Wednesday, August 6, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Nuvation Bio Earnings Headlines

Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
See More Nuvation Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvation Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvation Bio and other key companies, straight to your email.

About Nuvation Bio

Nuvation Bio (NYSE:NUVB), a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

View Nuvation Bio Profile

More Earnings Resources from MarketBeat